secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0000105770-22-000050
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q3 adj. EPS $2.03; cuts FY2022 guidance; raises dividend 5.6%
-------------------------------------------------------------------------

- Net sales $686.9M (-2.8% reported, +4.3% organic); HVP net sales mid-single digit organic growth.
- Reported EPS $1.59 (-31.2%); adjusted EPS $2.03 (-1.5%); Biologics and Generics mid-single digit organic growth.
- FY2022 guidance cut: net sales $2.830-2.840B (prior $2.950-2.975B), adjusted EPS $8.15-8.20 (prior $9.00-9.15).
- Dividend raised 5.6% to $0.19/share, payable Nov 16 to holders of record Nov 9; 30th consecutive annual increase.
- Management cited delays in expansion projects and customer mix-shift; expects resolution early 2023; capex guidance lowered to $300-320M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577022000050/0000105770-22-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577022000050/wst-20221027.htm
  HTML page:      https://secwatch.observer/filing/0000105770-22-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer